Empagliflozin decreases myocardial cytoplasmic Na+ through inhibition of the cardiac Na+/H+ exchanger in rats and rabbits

Diabetologia

Volumn 60, Issue 3, 2017, Pages 568-573

  Baartscheer, Antonius ^a   Schumacher, Cees A ^a   Wüst, Rob C I ^a,b   Fiolet, Jan W T ^a   Stienen, Ger J M ^b,c   Coronel, Ruben ^a,d   Zuurbier, Coert J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Calcium; Cardiac death; Diabetes; Glucose; Heart failure; Sodium

Indexed keywords

CARIPORIDE; EMPAGLIFLOZIN; GLUCOSE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM ION; SODIUM PROTON EXCHANGE PROTEIN; ANTIDIABETIC AGENT; BENZHYDRYL DERIVATIVE; CALCIUM; GLUCOSIDE; SODIUM;

ANIMAL CELL; ARTICLE; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIOVASCULAR RISK; CONTROLLED STUDY; CYTOPLASM; FLUOROMETRY; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN TRANSPORT; RABBIT; RAT; RISK REDUCTION; ANIMAL; ANTAGONISTS AND INHIBITORS; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; LEPORIDAE; METABOLISM;

ANIMALS; BENZHYDRYL COMPOUNDS; CALCIUM; CYTOPLASM; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HYPOGLYCEMIC AGENTS; MYOCARDIUM; MYOCYTES, CARDIAC; RABBITS; RATS; SODIUM; SODIUM-HYDROGEN ANTIPORTER;

EID: 84991712516     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4134-x     Document Type: Article

References (17)

1. Zinman B, Wanner C, Lachin JM et al (2015) EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes and mortality in type 2 diabetes. N Engl J Med 373:2117–2128
2. Marx N, McGuire DK (2016) Sodium-glucose cotransporter-2 inhibitor for the reduction of cardiovascular events in high-risk patients with diabetes mellitus. Eur Heart J. doi:10.1093/eurheartj/ehw110
3. +]i and underlies disturbed calcium handling in the rabbit pressure and volume overload heart failure model. Cardiovasc Res 57:1015–1024
4. + concentration is elevated in heart failure, but Na/K pump function is unchanged. Circulation 105:2543–2548
5. 2+ exchange prevents sudden cardiac death in a guinea pig model of heart failure. Circ Res 115:44–54
6. Pogwizd SM, Sipido KR, Verdonck F, Bers DM (2003) Intracellular Na in animal models of hypertrophy and heart failure: contractile function and arrhythmogenesis. Cardiovasc Res 57:887–896
7. 2+ uptake in myocytes from failing hearts restores energy supply and demand matching. Circ Res 103:279–288
8. 2+ transient in ventricular myocytes from streptozotocin-induced diabetic rats. Mol Cell Biochem 400:57–68
9. Van Steenbergen A, Balteau M, Scholasse J et al (2015) Identification of a glucose sensor in the heart. Eur Heart J 36 (Suppl 1):381(abstract)
10. i) is elevated in diabetic hearts due to enhanced Na + -glucose cotransport. J Am Heart Assoc 4, e002183
11. Vrhovac I, Balen Eror D, Klessen D et al (2015) Localizations of Na + -D-glucose cotransporters SGLT1 and SGLT2 in human kidney and of SGLT1 in human small intestine, liver, lung, and heart. Pflugers Arch 467:1881–1898
12. Heise T, Seman MS, Macha S (2013) Safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple rising doses of Empagliflozin in patients with type 2 diabetes mellitus. Diabetes Ther 4:331–345
13. Grempler R, Thomas L, Eckhardt M et al (2012) Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterization and comparison with other SGLT-2 inhibitors. Diabetes Obes Metab 14:83–90
14. + increases mitochondrial formation of reactive oxygen species in failing cardiac myocytes. Circulation 121:1606–1613
15. Balestra GM, Mik EG, Eerbeek O, Specht PA, van der Laarse WJ, Zuurbier CJ (2015) Increased in vivo mitochondrial oxygenation with right ventricular failure induced by pulmonary arterial hypertension: mitochondrial inhibition as driver of cardiac failure? Respir Res 16:6
16. Baartscheer A, Hardziyenka M, Schumacher CA (2008) Chronic inhibition of the Na+/H+ - exchanger causes regression of hypertrophy, heart failure, and ionic and electrophysiological remodeling. Br J Pharmacol 154:1266–1275
17. +-exchanger attenuates cardiac hypertrophy and prevents cellular remodeling in heart failure. Cardiovasc Res 65:83–92